HUSSEIN TAWBI to Drug Resistance, Neoplasm
This is a "connection" page, showing publications HUSSEIN TAWBI has written about Drug Resistance, Neoplasm.
Connection Strength
0.670
-
Resistance to anti-PD1 therapies in patients with advanced melanoma: systematic literature review and application of the Society for Immunotherapy of Cancer Immunotherapy Resistance Taskforce anti-PD1 resistance definitions. Melanoma Res. 2022 12 01; 32(6):393-404.
Score: 0.328
-
"Liquid Gold" - The unTAPped Potential of Cerebrospinal Fluid Analysis? Clin Cancer Res. 2020 05 01; 26(9):2083-2084.
Score: 0.069
-
Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies. Cancer Chemother Pharmacol. 2019 12; 84(6):1289-1301.
Score: 0.066
-
MicroRNA-125a promotes resistance to BRAF inhibitors through suppression of the intrinsic apoptotic pathway. Pigment Cell Melanoma Res. 2017 05; 30(3):328-338.
Score: 0.056
-
Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med. 2017 03 01; 9(379).
Score: 0.056
-
Chemotherapy resistance abrogation in metastatic melanoma. Clin Adv Hematol Oncol. 2010 Apr; 8(4):259-66.
Score: 0.034
-
Management of metastatic melanoma. Semin Oncol. 2007 Dec; 34(6):532-45.
Score: 0.029
-
CTLA-4 Blockade Resistance after Relatlimab and Nivolumab. N Engl J Med. 2022 04 28; 386(17):1668-1669.
Score: 0.020
-
Ligand-independent EPHA2 signaling drives the adoption of a targeted therapy-mediated metastatic melanoma phenotype. Cancer Discov. 2015 Mar; 5(3):264-73.
Score: 0.012